While much of research progress has been achieved in last century on Alzheimer’s Disease (AD), the conclusive therapy for the same is still unachieved. Several lines of therapeutic regimes have been introduced, which basically act on slowing down the disease progression.

Alzheimer’s disease (AD) is a global health crisis currently afflicting ~6 million Americans (and ~40 million people worldwide). By the middle of the century, these numbers will stagger by ~16 million Americans (and ~152 million people worldwide) suffering from AD, if breakthrough disease-modifying treatments are not discovered.

The continuous increase in the elderly population and chronic health conditions present significant challenges to healthcare systems, particularly in developing countries. Among these conditions, dementia, particularly Alzheimer's disease (AD), is one of the most concerning, causing cognitive decline, behavioral changes, and progressive dependence on family caregivers.

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline and memory impairment. One of the key pathological hallmarks of AD is the accumulation of amyloid beta (Aβ), a peptide derived from the sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretases .

Alzheimer’s disease (AD) is the leading cause of dementia, defined by amyloid plaques and neurofibrillary tangles. Yet, variability in disease onset and progression cannot be explained solely by pathology. Neuroplasticity, the brain’s ability to reorganize and adapt, is increasingly recognized as central to resilience in AD, with compelling evidence that it differs between sexes.